View ValuationHydration Pharmaceuticals 将来の成長Future 基準チェック /06現在、 Hydration Pharmaceuticalsの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Personal Products 収益成長13.8%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesBoard Change • May 20No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. Non-Executive Director Joseph Constable was the last director to join the board, commencing their role in 2025. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Apr 30The Hydration Pharmaceuticals Company Limited, Annual General Meeting, May 29, 2026The Hydration Pharmaceuticals Company Limited, Annual General Meeting, May 29, 2026.お知らせ • Jul 10The Hydration Pharmaceuticals Company Limited has completed a Follow-on Equity Offering in the amount of AUD 0.608879 million.The Hydration Pharmaceuticals Company Limited has completed a Follow-on Equity Offering in the amount of AUD 0.608879 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 13,387,853 Price\Range: AUD 0.01 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 3,000,000 Price\Range: AUD 0.01 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 39,500,000 Price\Range: AUD 0.01 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 5,000,000 Price\Range: AUD 0.01 Transaction Features: Rights Offeringお知らせ • Mar 25The Hydration Pharmaceuticals Company Limited has completed a Follow-on Equity Offering in the amount of AUD 0.65 million.The Hydration Pharmaceuticals Company Limited has completed a Follow-on Equity Offering in the amount of AUD 0.65 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 65,000,000 Price\Range: AUD 0.01 Transaction Features: Subsequent Direct Listingお知らせ • Mar 18+ 1 more updateThe Hydration Pharmaceuticals Company Limited has filed a Follow-on Equity Offering in the amount of AUD 0.609826 million.The Hydration Pharmaceuticals Company Limited has filed a Follow-on Equity Offering in the amount of AUD 0.609826 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 60,982,614 Price\Range: AUD 0.01 Transaction Features: Rights Offeringお知らせ • Mar 14The Hydration Pharmaceuticals Company Limited, Annual General Meeting, May 28, 2025The Hydration Pharmaceuticals Company Limited, Annual General Meeting, May 28, 2025.Board Change • Sep 03Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Independent Non-Executive Director Margaret Hardin was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Board Change • May 29Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Independent Non-Executive Director Margaret Hardin was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • May 24The Hydration Pharmaceuticals Company Limited Announces Board Change, Effective 25 May 2024The Hydration Pharmaceuticals Company Limited announced that further to the change of Board composition announced on 23 April 2024, and as part of the Company's continuous review of Board skills and composition, Mr. Nick Berry will be appointed as a non-executive Director, effective 25 May 2024. Mr. Nick Berry's appointment as non-executive director will be effective following the resignation of Mr. George Livery on 25 May 2024. Nick Berry brings over 19 years of experience in the Australian finance industry, specialising in equity and debt capital markets, mergers and acquisitions and strategic planning. With a proven track record in raising capital and structuring and negotiating complex financial transactions, Nick has demonstrated extensive expertise and leadership in the field. He previously served as an Executive Director at Nomura Australia and is currently a Director of PURE Asset Management Pty Ltd. Nick holds a Master of Engineering (MEng) from the University of Bath and is a Member of the Australian Institute of Company Directors.Reported Earnings • Mar 01Full year 2023 earnings released: US$0.04 loss per share (vs US$0.065 loss in FY 2022)Full year 2023 results: US$0.04 loss per share (improved from US$0.065 loss in FY 2022). Revenue: US$10.0m (up 10% from FY 2022). Net loss: US$8.10m (loss narrowed 24% from FY 2022).New Risk • Mar 01New major risk - Negative shareholders equityThe company has negative equity. Total equity: -US$358k This is considered a major risk. Being in negative equity means that the company's liabilities exceed its assets, meaning it owes more to creditors than it has in owned assets. While this doesn't mean the company is about to collapse, in the long-term, this is unsustainable. The company may have issues meeting financial obligations, is at risk of becoming insolvent and may have difficulty raising capital, especially more debt, if needed. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$5.7m free cash flow). Shares are highly illiquid. Negative equity (-US$358k). Earnings have declined by 16% per year over the past 5 years. Shareholders have been substantially diluted in the past year (62% increase in shares outstanding). Market cap is less than US$10m (AU$4.24m market cap, or US$2.76m).お知らせ • Feb 22The Hydration Pharmaceuticals Company Limited, Annual General Meeting, May 07, 2024The Hydration Pharmaceuticals Company Limited, Annual General Meeting, May 07, 2024.New Risk • Sep 21New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 56% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$8.3m free cash flow). Shares are highly illiquid. Earnings have declined by 19% per year over the past 5 years. Shareholders have been substantially diluted in the past year (56% increase in shares outstanding). Market cap is less than US$10m (AU$9.97m market cap, or US$6.40m).Reported Earnings • Sep 05First half 2023 earnings released: US$0.022 loss per share (vs US$0.026 loss in 1H 2022)First half 2023 results: US$0.022 loss per share (improved from US$0.026 loss in 1H 2022). Revenue: US$5.30m (up 28% from 1H 2022). Net loss: US$3.53m (loss narrowed 17% from 1H 2022).お知らせ • Aug 29The Hydration Pharmaceuticals Company Limited Announces Resignation of Gretta van Riel as Non-Executive Director, Effective September 26, 2023The Hydration Pharmaceuticals Company Limited announced that Ms. Gretta van Riel has resigned as a Non-Executive Director of the Company, effective from the 26th of September.New Risk • Aug 13New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 21% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$9.8m free cash flow). Shares are highly illiquid. Earnings have declined by 20% per year over the past 5 years. Market cap is less than US$10m (AU$7.12m market cap, or US$4.62m). Minor Risk Shareholders have been diluted in the past year (21% increase in shares outstanding).お知らせ • Aug 12The Hydration Pharmaceuticals Company Limited has completed a Follow-on Equity Offering in the amount of AUD 1.5 million.The Hydration Pharmaceuticals Company Limited has completed a Follow-on Equity Offering in the amount of AUD 1.5 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 33,333,337 Price\Range: AUD 0.045 Discount Per Security: AUD 0.0027 Security Features: Attached Options Transaction Features: Subsequent Direct ListingReported Earnings • Mar 01Full year 2022 earnings released: US$0.07 loss per share (vs US$0.12 loss in FY 2021)Full year 2022 results: US$0.07 loss per share. Revenue: US$9.10m (up 49% from FY 2021). Net loss: US$10.6m (loss widened 19% from FY 2021).お知らせ • Feb 08The Hydration Pharmaceuticals Company Limited Announces Executive ChangesThe Hydration Pharmaceuticals Company Limited announced the appointment of Victoria Nadalin as Company Secretary upon the resignation of Carlie Hodges, effective 8 February 2023. Victoria is a practising corporate and commercial lawyer and is completing a Graduate Diploma in Applied Corporate Governance and Risk Management with the Governance Institute of Australia. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Hydration Pharmaceuticals は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測CHIA:HPC - アナリストの将来予測と過去の財務データ ( )USD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/20252-3-4-4N/A9/30/20253-4-4-4N/A6/30/20253-5-3-3N/A3/31/20253-5-4-4N/A12/31/20243-6-4-4N/A6/30/20241-6-5-5N/A3/31/20243-7-5-5N/A12/31/20234-7-6-6N/A9/30/202310-9-7-7N/A6/30/202310-10-8-8N/A3/31/202310-10-9-9N/A12/31/20229-11-10-10N/A9/30/20229-11-9-9N/A6/30/20228-11-9-9N/A3/31/20227-10-9-9N/A12/31/20216-9-8-8N/A9/30/20215-6-7-7N/A6/30/20214-4-5-5N/A3/31/20214-2-3-4N/A12/31/20204-1-1-4N/A12/31/20193-3-3-3N/A12/31/20184-10N/A-5N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: HPCの予測収益成長が 貯蓄率 ( 3.6% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: HPCの収益がAustralian市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: HPCの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: HPCの収益がAustralian市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: HPCの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: HPCの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YHousehold 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/24 07:44終値2026/05/20 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋The Hydration Pharmaceuticals Company Limited 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
Board Change • May 20No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. Non-Executive Director Joseph Constable was the last director to join the board, commencing their role in 2025. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Apr 30The Hydration Pharmaceuticals Company Limited, Annual General Meeting, May 29, 2026The Hydration Pharmaceuticals Company Limited, Annual General Meeting, May 29, 2026.
お知らせ • Jul 10The Hydration Pharmaceuticals Company Limited has completed a Follow-on Equity Offering in the amount of AUD 0.608879 million.The Hydration Pharmaceuticals Company Limited has completed a Follow-on Equity Offering in the amount of AUD 0.608879 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 13,387,853 Price\Range: AUD 0.01 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 3,000,000 Price\Range: AUD 0.01 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 39,500,000 Price\Range: AUD 0.01 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 5,000,000 Price\Range: AUD 0.01 Transaction Features: Rights Offering
お知らせ • Mar 25The Hydration Pharmaceuticals Company Limited has completed a Follow-on Equity Offering in the amount of AUD 0.65 million.The Hydration Pharmaceuticals Company Limited has completed a Follow-on Equity Offering in the amount of AUD 0.65 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 65,000,000 Price\Range: AUD 0.01 Transaction Features: Subsequent Direct Listing
お知らせ • Mar 18+ 1 more updateThe Hydration Pharmaceuticals Company Limited has filed a Follow-on Equity Offering in the amount of AUD 0.609826 million.The Hydration Pharmaceuticals Company Limited has filed a Follow-on Equity Offering in the amount of AUD 0.609826 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 60,982,614 Price\Range: AUD 0.01 Transaction Features: Rights Offering
お知らせ • Mar 14The Hydration Pharmaceuticals Company Limited, Annual General Meeting, May 28, 2025The Hydration Pharmaceuticals Company Limited, Annual General Meeting, May 28, 2025.
Board Change • Sep 03Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Independent Non-Executive Director Margaret Hardin was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Board Change • May 29Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Independent Non-Executive Director Margaret Hardin was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • May 24The Hydration Pharmaceuticals Company Limited Announces Board Change, Effective 25 May 2024The Hydration Pharmaceuticals Company Limited announced that further to the change of Board composition announced on 23 April 2024, and as part of the Company's continuous review of Board skills and composition, Mr. Nick Berry will be appointed as a non-executive Director, effective 25 May 2024. Mr. Nick Berry's appointment as non-executive director will be effective following the resignation of Mr. George Livery on 25 May 2024. Nick Berry brings over 19 years of experience in the Australian finance industry, specialising in equity and debt capital markets, mergers and acquisitions and strategic planning. With a proven track record in raising capital and structuring and negotiating complex financial transactions, Nick has demonstrated extensive expertise and leadership in the field. He previously served as an Executive Director at Nomura Australia and is currently a Director of PURE Asset Management Pty Ltd. Nick holds a Master of Engineering (MEng) from the University of Bath and is a Member of the Australian Institute of Company Directors.
Reported Earnings • Mar 01Full year 2023 earnings released: US$0.04 loss per share (vs US$0.065 loss in FY 2022)Full year 2023 results: US$0.04 loss per share (improved from US$0.065 loss in FY 2022). Revenue: US$10.0m (up 10% from FY 2022). Net loss: US$8.10m (loss narrowed 24% from FY 2022).
New Risk • Mar 01New major risk - Negative shareholders equityThe company has negative equity. Total equity: -US$358k This is considered a major risk. Being in negative equity means that the company's liabilities exceed its assets, meaning it owes more to creditors than it has in owned assets. While this doesn't mean the company is about to collapse, in the long-term, this is unsustainable. The company may have issues meeting financial obligations, is at risk of becoming insolvent and may have difficulty raising capital, especially more debt, if needed. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$5.7m free cash flow). Shares are highly illiquid. Negative equity (-US$358k). Earnings have declined by 16% per year over the past 5 years. Shareholders have been substantially diluted in the past year (62% increase in shares outstanding). Market cap is less than US$10m (AU$4.24m market cap, or US$2.76m).
お知らせ • Feb 22The Hydration Pharmaceuticals Company Limited, Annual General Meeting, May 07, 2024The Hydration Pharmaceuticals Company Limited, Annual General Meeting, May 07, 2024.
New Risk • Sep 21New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 56% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$8.3m free cash flow). Shares are highly illiquid. Earnings have declined by 19% per year over the past 5 years. Shareholders have been substantially diluted in the past year (56% increase in shares outstanding). Market cap is less than US$10m (AU$9.97m market cap, or US$6.40m).
Reported Earnings • Sep 05First half 2023 earnings released: US$0.022 loss per share (vs US$0.026 loss in 1H 2022)First half 2023 results: US$0.022 loss per share (improved from US$0.026 loss in 1H 2022). Revenue: US$5.30m (up 28% from 1H 2022). Net loss: US$3.53m (loss narrowed 17% from 1H 2022).
お知らせ • Aug 29The Hydration Pharmaceuticals Company Limited Announces Resignation of Gretta van Riel as Non-Executive Director, Effective September 26, 2023The Hydration Pharmaceuticals Company Limited announced that Ms. Gretta van Riel has resigned as a Non-Executive Director of the Company, effective from the 26th of September.
New Risk • Aug 13New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 21% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$9.8m free cash flow). Shares are highly illiquid. Earnings have declined by 20% per year over the past 5 years. Market cap is less than US$10m (AU$7.12m market cap, or US$4.62m). Minor Risk Shareholders have been diluted in the past year (21% increase in shares outstanding).
お知らせ • Aug 12The Hydration Pharmaceuticals Company Limited has completed a Follow-on Equity Offering in the amount of AUD 1.5 million.The Hydration Pharmaceuticals Company Limited has completed a Follow-on Equity Offering in the amount of AUD 1.5 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 33,333,337 Price\Range: AUD 0.045 Discount Per Security: AUD 0.0027 Security Features: Attached Options Transaction Features: Subsequent Direct Listing
Reported Earnings • Mar 01Full year 2022 earnings released: US$0.07 loss per share (vs US$0.12 loss in FY 2021)Full year 2022 results: US$0.07 loss per share. Revenue: US$9.10m (up 49% from FY 2021). Net loss: US$10.6m (loss widened 19% from FY 2021).
お知らせ • Feb 08The Hydration Pharmaceuticals Company Limited Announces Executive ChangesThe Hydration Pharmaceuticals Company Limited announced the appointment of Victoria Nadalin as Company Secretary upon the resignation of Carlie Hodges, effective 8 February 2023. Victoria is a practising corporate and commercial lawyer and is completing a Graduate Diploma in Applied Corporate Governance and Risk Management with the Governance Institute of Australia.